

**PharmaEssentia™**

**BESREMi Brand Outline**

# brand story

## BESREMi brand outline

### What does BESREMi do?

#### Targets the source of Polycythemia Vera (PV)

- Works in the bone marrow to manage the disease where it grows.

### What does BESREMi do?

#### The only FDA-approved agent across all lines of treatment

#### The only NCCN-recommended agent across all lines of treatment

- Studied in a broad range of patients with PV
  - Low- and high-risk
  - Newly diagnosed
  - HU treatment-naïve
  - Pretreated with HU/phlebotomy

### Why should BESREMi be believed?

#### High and durable rates of comprehensive disease control in low- and high-risk patients

- PEGINVERA
  - 61% achieved comprehensive disease control\* over 7.5 years, with no thromboembolic events
  - 80% achieved CHR† over 7.5 years
- Low-PV study
  - 84% achieved Hct control with no disease progression‡

#### Manageable long-term safety and tolerability

Patients are able to remain on therapy as demonstrated in multiple clinical trials, from 12 months to 7.5 years of treatment (N=228)

- PEGINVERA
- PROUD/ CONTINUATION
- Low-PV study
- No cases of AML and 1 case of MF observed over 7.5 years
- Unique PK properties extend the dosing interval to support long-term adherence to therapy
  - 1 dose every 2 weeks, which can be extended to 1 dose every 4 weeks

\* Defined as hematocrit <45%, no phlebotomy in the past 2 months, leukocyte count  $\leq 10 \times 10^9/L$ , platelet count  $< 400 \times 10^9/L$ , normal spleen size, and absence of thromboembolic events.

† Defined as hematocrit <45%, no phlebotomy in the past 2 months, leukocyte count  $\leq 10 \times 10^9/L$ , and platelet count  $< 400 \times 10^9/L$ .

‡ Defined as maintenance of median Hct <45% over 12 months with an absence of progressive symptomatic thrombocytosis, progressive leukocytosis, and any vascular or major bleeding complication.